FF305 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2025年10月21日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 ...

Core Points - The company, Yidu Tech (02158), announced a share buyback on October 20, spending HKD 370,000 to repurchase 66,200 shares [1] - In the past week, Yidu Tech has conducted four buybacks, totaling approximately 2.751 million shares and over HKD 16 million in total buyback amount [1] - Since September 26, the company has completed six buybacks, with a cumulative buyback amount nearing HKD 20 million [1] Market Activity - According to the latest data, southbound funds net bought 3.5762 million shares of Yidu Tech on October 15, accounting for 32.24% of the day's trading volume [1] - In terms of net buying amount, southbound funds net purchased Yidu Tech shares worth HKD 21.1353 million on that day, marking four consecutive days of net buying, with a total net purchase of HKD 78.07 million [1]

最近一周医渡科技已累计进行4次回购，合计回购约275.1万股，累计回购金额超过1600万港元。若将时 间线拉长至9月26日起，该股已完成6次回购，累计回购金额近2000万港元。 市场资金动向方面，据Wind最新数据，南向资金10月15日净买入医渡科技357.62万股，占当日成交量比 例为32.24%。从增减持金额来看，以增减持数量和成交均价为基准进行测算，南向资金当日净买入医 渡科技2113.53万港元，连续4日净买入，累计净买入7807万港元。 智通财经APP获悉，根据医渡科技(02158)最新公告，公司于10月20日再次回购股份，单日斥资37万港元 购回6.62万股。 ...

医渡科技(02158)发布公告，于2025年10月20日，该公司斥资37.23万港元回购6.62万股股份，每股回购 价格为5.59-5.65港元。 ...

智通财经APP讯，医渡科技(02158)发布公告，于2025年10月20日，该公司斥资37.23万港元回购6.62万股 股份，每股回购价格为5.59-5.65港元。 ...

格隆汇10月20日丨医渡科技(02158.HK)公告，10月20日耗资37.2万港元回购6.6万股，每股回购价5.59- 5.65港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2025年10月20日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 ...

Summary of Key Points Core Viewpoint - 医渡科技 has been actively repurchasing its shares, indicating confidence in its market position and future prospects [1] Group 1: Share Buyback Activity - On October 17, 医渡科技 spent HKD 1.013 million to repurchase 181,000 shares [1] - This week, the company has conducted three buybacks totaling approximately 2.685 million shares, with a total expenditure exceeding HKD 15.6 million [1] - Since September 26, the company has executed five buybacks, amounting to around 3.373 million shares and nearly HKD 20 million in total [1] Group 2: Southbound Capital Inflows - On October 14, southbound funds net purchased HKD 34.7273 million worth of 医渡科技 shares, marking the highest net inflow since September 1, 2025 [1] - The net buying has continued for three consecutive days, with a cumulative net purchase of HKD 57.79 million [1] Group 3: Product Development and Market Support - Recently, the world's first topical treatment for proliferative superficial infantile hemangioma, Timolol Maleate Gel, has been approved for market release [1] - 医渡科技 provided critical market research and project analysis services that supported the drug's development and market entry [1]

Core Viewpoint - 医渡科技 announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company plans to repurchase 181,200 shares at a total cost of HKD 1.0131 million [1] - The buyback price per share ranges from HKD 5.56 to HKD 5.65 [1] - The buyback is scheduled for October 17, 2025, reflecting a strategic move to enhance shareholder value [1]

智通财经APP讯，医渡科技(02158)发布公告，于2025年10月17日，该公司斥资101.31万港元回购18.12万 股股份，每股回购价格为5.56-5.65港元。 ...